The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Resistance to chemotherapy: new treatments and novel insights into an old problem
Open accessAbstract
Resistance to cancer chemotherapeutic treatment is a common phenomenon, especially in progressive disease. The generation of cellular models of drug resistance has been pivotal in unravelling the main effectors of resistance to traditional chemotherapy at the molecular level (i.e. intracellular drug inactivation, detoxifying systems, defects in DNA repair, apoptosis evasion, membrane transporters and cell adhesion). The development of targeted therapies has also been followed by resistance, reminiscent of an evolutionary arms race, as exemplified by imatinib and other BCR-ABL inhibitors for the treatment of chronic myelogenous leukaemia. Although traditionally associated with the last stages of the disease, recent findings with minimally transformed pretumorigenic primary human cells indicate that the ability to generate drug resistance arises early during the tumorigenic process, before the full transformation. Novel technologies, such as genome profiling, have in certain cases predicted the outcome of chemotherapy and undoubtedly have tremendous potential for the future. In addition, the novel cancer stem cell paradigm raises the prospect of cell-targeted therapies instead of treatment directed against the whole tumour.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 2×
“Most clinical trial end points have not been analysed yet; for an extended discussion of P-glycoprotein inhibitors in the clinic see Szakacs et al (2006).”
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Endocrine-responsive breast cancer and strategies for combating resistance
Ali, S., & Coombes, R. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc721 · Cited by 883
GOODMAN, L. S. (1946) · Journal of the American Medical Association · doi:10.1001/jama.1946.02870380008004 · Cited by 700
Normal Stem Cells and Cancer Stem Cells: The Niche Matters
Li, L., & Neaves, W. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3986 · Cited by 675
Weisberg, E., Manley, P. W., Cowan-Jacob, S. W., Hochhaus, A., & Griffin, J. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2126 · Cited by 636
Chronic myeloid leukaemia as a model of disease evolution in human cancer
Melo, J. V., & Barnes, D. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2147 · Cited by 623
Zhou, S., Morris, J. J., Barnes, Y., Lan, L., Schuetz, J. D., & Sorrentino, B. P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192276999 · Cited by 502
Targeting Tyrosine Kinases in Cancer: The Second Wave
Baselga, J. (2006) · Science · doi:10.1126/science.1125951 · Cited by 478
Sotiriou, C., & Piccart, M. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2173 · Cited by 461
Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis
Donnenberg, V. S., & Donnenberg, A. D. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005276905 · Cited by 457
Le Cesne, A., Blay, J. Y., Judson, I., Van Oosterom, A., Verweij, J., Radford, J., Lorigan, P., Rodenhuis, S., Ray-Coquard, I., Bonvalot, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.180 · Cited by 421
Growth Factors in Breast Cancer
DICKSON, R. B., & LIPPMAN, M. E. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-5-559 · Cited by 388
Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm
Soussi, T., & Wiman, K. G. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.001 · Cited by 368
Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling
Jansen, M. P. H. M., Foekens, J. A., van Staveren, I. L., Dirkzwager-Kiel, M. M., Ritstier, K., Look, M. P., Meijer-van Gelder, M. E., Sieuwerts, A. M., Portengen, H., Dorssers, L. C. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.145 · Cited by 340
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia
Wulf, G. G., Wang, R.-Y., Kuehnle, I., Weidner, D., Marini, F., Brenner, M. K., Andreeff, M., & Goodell, M. A. (2001) · Blood · doi:10.1182/blood.v98.4.1166 · Cited by 326
What has senescence got to do with cancer?
Dimri, G. P. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.025 · Cited by 313
Membrane Transporters and Channels
Huang, Y., Anderle, P., Bussey, K. J., Barbacioru, C., Shankavaram, U., Dai, Z., Reinhold, W. C., Papp, A., Weinstein, J. N., & Sadée, W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3884 · Cited by 285
(1949) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1949.tb68027.x · Cited by 215
Darwinian medicine: a case for cancer
Greaves, M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2071 · Cited by 180
Schiff, R., Massarweh, S. A., Shou, J., Bharwani, L. D., Arpino, G., Rimawi, M. F., & Osborne, C. K. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0108-2 · Cited by 165
Multidrug Resistance/P-Glycoprotein and Breast Cancer: Review and Meta-Analysis
Clarke, R., Leonessa, F., & Trock, B. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.009 · Cited by 159
Stem cells and cancer: an intimate relationship
Burkert, J., Wright, N., & Alison, M. R. (2006) · The Journal of Pathology · doi:10.1002/path.2016 · Cited by 155
Turton, N. J., Judah, D. J., Riley, J., Davies, R., Lipson, D., Styles, J. A., Smith, A. G., & Gant, T. W. (2001) · Oncogene · doi:10.1038/sj.onc.1204235 · Cited by 125
ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance
de Jonge-Peeters, S. D. P. W. M., Kuipers, F., de Vries, E. G. E., & Vellenga, E. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.02.003 · Cited by 120
Ability to Acquire Drug Resistance Arises Early during the Tumorigenesis Process
Yagüe, E., Arance, A. M., Kubitza, L., O’Hare, M. J., Jat, P., Ogilvie, C. M., Hart, I. R., Higgins, C. F., & Raguz, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2574 · Cited by 66
Self-citationMitotic Catastrophe as a Consequence of Chemotherapy
Mansilla, S., Bataller, M., & Portugal, J. (2006) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152006778699086 · Cited by 65
Pharmacokinetics in cancer chemotherapy
Garattini, S. K. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.10.015 · Cited by 49
Alaoui‐Jamali, M. A., DUPRE, I., & Qiang, H. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.06.004 · Cited by 44
Cimoli, G., Malacarne, D., Ponassi, R., Valenti, M., Alberti, S., & Parodi, S. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2004.10.001 · Cited by 41
New approaches to reverse resistance to hormonal therapy in human breast cancer
Weinberg, O. K., Márquez‐Garbán, D. C., & Pietras, R. J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.06.002 · Cited by 40
Understanding transformation: progress and gaps
Boehm, J. S., & Hahn, W. C. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.11.003 · Cited by 37
Cited by
Wang, Y., Xing, M., Cao, Q., Ji, A., Liang, H., & Song, S. (2019) · Marine Drugs · doi:10.3390/md17030183 · Cited by 506
Goel, A., & Aggarwal, B. B. (2010) · Nutrition and Cancer · doi:10.1080/01635581.2010.509835 · Cited by 464
Molecular aspects of cancer cell resistance to chemotherapy
Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 407
Pogribny, I. P., Filkowski, J. N., Tryndyak, V. P., Golubov, A., Shpyleva, S. I., & Kovalchuk, O. (2010) · International Journal of Cancer · doi:10.1002/ijc.25191 · Cited by 334
O’Donovan, T. R., O’Sullivan, G. C., & McKenna, S. L. (2011) · Autophagy · doi:10.4161/auto.7.5.15066 · Cited by 279
Metadata
- Authors
- Raguz, S., & Yagüe, E.
- Venue
- British Journal of Cancer
- Published
- 2008-07-29
- Volume
- 99
- Issue
- 3
- Pages
- 387-391
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2092677877
- Cited by
- 312
- References
- 43
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.